Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Edward H. Romond, M.D., Edith A. Perez, M.D., John Bryant, Ph.D., Vera J. Suman, Ph.D., Charles E. Geyer, Jr., M.D., Nancy E. Davidson, M.D., Elizabeth Tan-Chiu, M.D., Silvana Martino, D.O., Soonmyung Paik, M.D., Peter A. Kaufman, M.D., Sandra M. Swain, M.D., Thomas M. Pisansky, M.D., Louis Fehrenbacher, M.D., Leila A. Kutteh, M.D., Victor G. Vogel, M.D., Daniel W. Visscher, M.D., Greg Yothers, Ph.D., Robert B. Jenkins, M.D., Ph.D., Ann M. Brown, Sc.D., Shaker R. Dakhil, M.D., Eleftherios P. Mamounas, M.D., M.P.H., Wilma L. Lingle, Ph.D., Pamela M. Klein, M.D., James N. Ingle, M.D., and Norman Wolmark, M.D.
Background We present the combined results of two trials thatcompared adjuvant chemotherapy with or without concurrent trastuzumabin women with surgically removed HER2-positive breast cancer.
Methods The National Surgical Adjuvant Breast and Bowel Projecttrial B-31 compared doxorubicin and cyclophosphamide followedby paclitaxel every 3 weeks (group 1) with the same regimenplus 52 weeks of trastuzumab beginning with the first dose ofpaclitaxel (group 2). The North Central Cancer Treatment Grouptrial N9831 compared three regimens: doxorubicin and cyclophosphamidefollowed by weekly paclitaxel (group A), the same regimen followedby 52 weeks of trastuzumab after paclitaxel (group B), and thesame regimen plus 52 weeks of trastuzumab initiated concomitantlywith paclitaxel (group C). The studies were amended to includea joint analysis comparing groups 1 and A (the control group)with groups 2 and C (the trastuzumab group). Group B was excludedbecause trastuzumab was not given concurrently with paclitaxel.
Results By March 15, 2005, 394 events (recurrent, second primarycancer, or death before recurrence) had been reported, triggeringthe first scheduled interim analysis. Of these, 133 were inthe trastuzumab group and 261 in the control group (hazard ratio,0.48; P<0.0001). This result crossed the early stopping boundary.The absolute difference in disease-free survival between thetrastuzumab group and the control group was 12 percent at threeyears. Trastuzumab therapy was associated with a 33 percentreduction in the risk of death (P=0.015). The three-year cumulativeincidence of class III or IV congestive heart failure or deathfrom cardiac causes in the trastuzumab group was 4.1 percentin trial B-31 and 2.9 percent in trial N9831.
Conclusions Trastuzumab combined with paclitaxel after doxorubicinand cyclophosphamide improves outcomes among women with surgicallyremoved HER2-positive breast cancer. (ClinicalTrials.gov numbers,NCT00004067
[ClinicalTrials.gov]
and NCT00005970
[ClinicalTrials.gov]
.)
Source Information
From the National Surgical Adjuvant Breast and Bowel Project, Pittsburgh (E.H.R., J.B., C.E.G., E.T.-C., S.P., S.M.S., L.F., V.G.V., G.Y., A.M.B., E.P.M., N.W.); University of Kentucky, Lexington (E.H.R.); North Central Cancer Treatment Group, Rochester, Minn. (E.A.P., V.J.S., T.M.P., L.A.K., D.W.V., R.B.J., S.R.D., W.L.L., J.N.I.); Mayo Clinic Jacksonville, Jacksonville, Fla. (E.A.P.); University of Pittsburgh, Pittsburgh (J.B., G.Y.); Mayo Clinic, Rochester, Minn. (V.J.S., T.M.P., D.W.V., R.B.J., W.L.L., J.N.I.); Allegheny General Hospital, Pittsburgh (C.E.G., N.W.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (N.E.D.), the Cancer Research Network, Plantation, Fla. (E.T.-C.); Angeles Clinic and Research Institute, Santa Monica, Calif. (S.M.); Norris Cotton Cancer Center, Dartmouth–Hitchcock Medical Center, Lebanon, N.H. (P.A.K.); Cancer Therapeutics Branch, National Cancer Institute, Bethesda, Md. (S.M.S.); Kaiser Permanente Medical Center Northern California, Vallejo (L.F.); Oncology Associates of Cedar Rapids, Cedar Rapids, Iowa (L.A.K.); University of Pittsburgh Cancer Institute, Pittsburgh (V.G.V.); Wichita Community Clinical Oncology Program, Wichita, Kans. (S.R.D.); Aultman Health Foundation, Canton, Ohio (E.P.M.); and Genentech, South San Francisco, Calif. (P.M.K.). Drs. Romond and Perez contributed equally to the article.
Address reprint requests to Dr. Geyer at the Allegheny Cancer Center, 5th Fl., 320 E. North Ave., Pittsburgh, PA 15212, or at cgeyer{at}wpahs.org.
Trastuzumab in Breast Cancer
Gilbert S. G., Banna G. L., Santoro A., Gounaris I. G., Katsumata M., Drebin J. A., Greene M. I., Mastrianni D. M., Mano M., Cameron D., Gelber R. D., the HERA Trial Study Team , Bryant J., Romond E., Perez E. A., Hortobagyi G. N., Barron H.
Extract |
Full Text |
PDF
N Engl J Med 2006;
354:640-644, Feb 9, 2006.
Correspondence
This article has been cited by other articles:
Lee, T. H., Emanuel, E. J.
(2008). Tier 4 Drugs and the Fraying of the Social Compact. NEJM
359: 333-335
[Full Text]
Dang, C., Norton, L., Hudis, C.
(2008). Dose-Dense Chemotherapy With Trastuzumab Is an Appropriate Option. JCO
26: 3655-3656
[Full Text]
Turner, N. C, Jones, A. L
(2008). Management of breast cancer--Part II. BMJ
337: a540-a540
[Full Text]
Peppercorn, J., Partridge, A. H.
(2008). Breast Cancer in Young Women: A New Color or a Different Shade of Pink?. JCO
26: 3303-3305
[Full Text]
Rowe, D. L., Ozbay, T., Bender, L. M., Nahta, R.
(2008). Nordihydroguaiaretic acid, a cytotoxic insulin-like growth factor-I receptor/HER2 inhibitor in trastuzumab-resistant breast cancer. Molecular Cancer Therapeutics
7: 1900-1908
[Abstract][Full Text]
Trotta, F., Apolone, G., Garattini, S., Tafuri, G.
(2008). Stopping a trial early in oncology: for patients or for industry?. Ann Oncol
19: 1347-1353
[Abstract][Full Text]
Walker, R A, Bartlett, J M S, Dowsett, M, Ellis, I O, Hanby, A M, Jasani, B, Miller, K, Pinder, S E
(2008). HER2 testing in the UK: further update to recommendations. J. Clin. Pathol.
61: 818-824
[Abstract][Full Text]
Gomez, H. L., Doval, D. C., Chavez, M. A., Ang, P. C.-S., Aziz, Z., Nag, S., Ng, C., Franco, S. X., Chow, L. W.C., Arbushites, M. C., Casey, M. A., Berger, M. S., Stein, S. H., Sledge, G. W.
(2008). Efficacy and Safety of Lapatinib As First-Line Therapy for ErbB2-Amplified Locally Advanced or Metastatic Breast Cancer. JCO
26: 2999-3005
[Abstract][Full Text]
Conrad, H., Gebhard, K., Kronig, H., Neudorfer, J., Busch, D. H., Peschel, C., Bernhard, H.
(2008). CTLs Directed against HER2 Specifically Cross-React with HER3 and HER4. J. Immunol.
180: 8135-8145
[Abstract][Full Text]
Menard, S., Balsari, A., Tagliabue, E., Camerini, T., Casalini, P., Bufalino, R., Castiglioni, F., Carcangiu, M. L., Gloghini, A., Scalone, S., Querzoli, P., Lunardi, M., Molino, A., Mandara, M., Mottolese, M., Marandino, F., Venturini, M., Bighin, C., Cancello, G., Montagna, E., Perrone, F., De Matteis, A., Sapino, A., Donadio, M., Battelli, N., Santinelli, A., Pavesi, L., Lanza, A., Zito, F. A., Labriola, A., Aiello, R. A., Caruso, M., Zanconati, F., Mustacchi, G., Barbareschi, M., Frisinghelli, M., Russo, R., Carrillo, G., On the behalf of the OMERO group,
(2008). Biology, prognosis and response to therapy of breast carcinomas according to HER2 score. Ann Oncol
0: mdn369v1-mdn369
[Abstract][Full Text]
Hines, S. L., Vallow, L. A., Tan, W. W., McNeil, R. B., Perez, E. A., Jain, A.
(2008). Clinical outcomes after a diagnosis of brain metastases in patients with estrogen- and/or human epidermal growth factor receptor 2-positive versus triple-negative breast cancer. Ann Oncol
0: mdn283v1-mdn283
[Abstract][Full Text]
Hudis, C., Dang, C.
(2008). The Taxane Limbo: How Low Can We Go?. JNCI J Natl Cancer Inst
100: 761-763
[Full Text]
Mayer, M.
(2008). Swimming Upstream: An Advocate Reflects on Cancer Research and Social Realities. JCO
26: 2783-2786
[Full Text]
MacKenzie, R., Chapman, S., Salkeld, G., Holding, S.
(2008). Media influence on Herceptin subsidization in Australia: application of the rule of rescue?. JRSM
101: 305-312
[Abstract][Full Text]
Kulkarni, S., Hicks, D. G.
(2008). HER2-Positive Early Breast Cancer and Trastuzumab: A Surgeon's Perspective. Ann. Surg. Oncol.
15: 1677-1688
[Abstract][Full Text]
Untch, M., Gelber, R. D., Jackisch, C., Procter, M., Baselga, J., Bell, R., Cameron, D., Bari, M., Smith, I., Leyland-Jones, B., de Azambuja, E., Wermuth, P., Khasanov, R., Feng-yi, F., Constantin, C., Mayordomo, J. I., Su, C.-H., Yu, S.-Y., Lluch, A., Senkus-Konefka, E., Price, C., Haslbauer, F., Sahui, T. S., Srimuninnimit, V., Colleoni, M., Coates, A. S., Piccart-Gebhart, M. J., Goldhirsch, A., for the HERA Study Team,
(2008). Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol
19: 1090-1096
[Abstract][Full Text]
Belkacemi, Y., Gligorov, J., Ozsahin, M., Marsiglia, H., De Lafontan, B., Laharie-Mineur, H., Aimard, L., Antoine, E.-C., Cutuli, B., Namer, M., Azria, D.
(2008). Concurrent trastuzumab with adjuvant radiotherapy in HER2-positive breast cancer patients: acute toxicity analyses from the French multicentric study. Ann Oncol
19: 1110-1116
[Abstract][Full Text]
Walker, R A
(2008). Immunohistochemical markers as predictive tools for breast cancer. J. Clin. Pathol.
61: 689-696
[Abstract][Full Text]
Dahabreh, I. J., Linardou, H., Siannis, F., Fountzilas, G., Murray, S.
(2008). Trastuzumab in the Adjuvant Treatment of Early-Stage Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. The Oncologist
13: 620-630
[Abstract][Full Text]
Contessa, J. N., Bhojani, M. S., Freeze, H. H., Rehemtulla, A., Lawrence, T. S.
(2008). Inhibition of N-Linked Glycosylation Disrupts Receptor Tyrosine Kinase Signaling in Tumor Cells. Cancer Res.
68: 3803-3809
[Abstract][Full Text]
Song, H., Shahverdi, K., Huso, D. L., Esaias, C., Fox, J., Liedy, A., Zhang, Z., Reilly, R. T., Apostolidis, C., Morgenstern, A., Sgouros, G.
(2008). 213Bi ({alpha}-Emitter)-Antibody Targeting of Breast Cancer Metastases in the neu-N Transgenic Mouse Model. Cancer Res.
68: 3873-3880
[Abstract][Full Text]
Northey, J. J., Chmielecki, J., Ngan, E., Russo, C., Annis, M. G., Muller, W. J., Siegel, P. M.
(2008). Signaling through ShcA Is Required for Transforming Growth Factor {beta}- and Neu/ErbB-2-Induced Breast Cancer Cell Motility and Invasion. Mol. Cell. Biol.
28: 3162-3176
[Abstract][Full Text]
King, J., Waxman, J., Stauss, H.
(2008). Advances in tumour immunotherapy. QJM
0: hcn050v1-hcn050
[Abstract][Full Text]
Rayson, D., Richel, D., Chia, S., Jackisch, C., van der Vegt, S., Suter, T.
(2008). Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies. Ann Oncol
0: mdn292v1-mdn292
[Abstract][Full Text]
DiGiovanna, M. P., Stern, D. F., Edgerton, S., Broadwater, G., Dressler, L. G., Budman, D. R., Henderson, I. C., Norton, L., Liu, E. T., Muss, H. B., Berry, D. A., Hayes, D. F., Thor, A. D.
(2008). Influence of Activation State of ErbB-2 (HER-2) on Response to Adjuvant Cyclophosphamide, Doxorubicin, and Fluorouracil for Stage II, Node-Positive Breast Cancer: Study 8541 From the Cancer and Leukemia Group B. JCO
26: 2364-2372
[Abstract][Full Text]
Nguyen, P. L., Taghian, A. G., Katz, M. S., Niemierko, A., Abi Raad, R. F., Boon, W. L., Bellon, J. R., Wong, J. S., Smith, B. L., Harris, J. R.
(2008). Breast Cancer Subtype Approximated by Estrogen Receptor, Progesterone Receptor, and HER-2 Is Associated With Local and Distant Recurrence After Breast-Conserving Therapy. JCO
26: 2373-2378
[Abstract][Full Text]
Muller, M., Obeyesekere, M., Mills, G. B., Ram, P. T.
(2008). Network topology determines dynamics of the mammalian MAPK1,2 signaling network: bifan motif regulation of C-Raf and B-Raf isoforms by FGFR and MC1R. FASEB J.
22: 1393-1403
[Abstract][Full Text]
Ignatiadis, M., Kallergi, G., Ntoulia, M., Perraki, M., Apostolaki, S., Kafousi, M., Chlouverakis, G., Stathopoulos, E., Lianidou, E., Georgoulias, V., Mavroudis, D.
(2008). Prognostic Value of the Molecular Detection of Circulating Tumor Cells Using a Multimarker Reverse Transcription-PCR Assay for Cytokeratin 19, Mammaglobin A, and HER2 in Early Breast Cancer. Clin. Cancer Res.
14: 2593-2600
[Abstract][Full Text]
Portera, C. C., Walshe, J. M., Rosing, D. R., Denduluri, N., Berman, A. W., Vatas, U., Velarde, M., Chow, C. K., Steinberg, S. M., Nguyen, D., Yang, S. X., Swain, S. M.
(2008). Cardiac Toxicity and Efficacy of Trastuzumab Combined with Pertuzumab in Patients with Trastuzumab-Insensitive Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. Clin. Cancer Res.
14: 2710-2716
[Abstract][Full Text]
Sargent, D. J., Hayes, D. F.
(2008). Assessing the Measure of a New Drug: Is Survival the Only Thing That Matters?. JCO
26: 1922-1923
[Full Text]
Lin, N. U., Carey, L. A., Liu, M. C., Younger, J., Come, S. E., Ewend, M., Harris, G. J., Bullitt, E., Van den Abbeele, A. D., Henson, J. W., Li, X., Gelman, R., Burstein, H. J., Kasparian, E., Kirsch, D. G., Crawford, A., Hochberg, F., Winer, E. P.
(2008). Phase II Trial of Lapatinib for Brain Metastases in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. JCO
26: 1993-1999
[Abstract][Full Text]
Montemurro, F., Redana, S., Valabrega, G., Martinello, R., Aglietta, M., Palmiero, R.
(2008). Trastuzumab-Related Cardiotoxicity in the Herceptin Adjuvant Trial. JCO
26: 2052-2053
[Full Text]
Oldham, R. K., Dillman, R. O.
(2008). Monoclonal Antibodies in Cancer Therapy: 25 Years of Progress. JCO
26: 1774-1777
[Full Text]
Seidman, A. D., Berry, D., Cirrincione, C., Harris, L., Muss, H., Marcom, P. K., Gipson, G., Burstein, H., Lake, D., Shapiro, C. L., Ungaro, P., Norton, L., Winer, E., Hudis, C.
(2008). Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840. JCO
26: 1642-1649
[Abstract][Full Text]
Paik, S., Kim, C., Wolmark, N.
(2008). HER2 Status and Benefit from Adjuvant Trastuzumab in Breast Cancer. NEJM
358: 1409-1411
[Full Text]
Pant, S., Landon, M. B., Blumenfeld, M., Farrar, W., Shapiro, C. L.
(2008). Treatment of Breast Cancer With Trastuzumab During Pregnancy. JCO
26: 1567-1569
[Full Text]
Mayer, E. L., Burstein, H. J.
(2008). Weighing a Dose-Dense Option for Adjuvant Chemotherapy and Trastuzumab in Early-Stage Breast Cancer. JCO
26: 1198-1200
[Full Text]
Dang, C., Fornier, M., Sugarman, S., Troso-Sandoval, T., Lake, D., D'Andrea, G., Seidman, A., Sklarin, N., Dickler, M., Currie, V., Gilewski, T., Moynahan, M. E., Drullinsky, P., Robson, M., Wasserheit-Leiblich, C., Mills, N., Steingart, R., Panageas, K., Norton, L., Hudis, C.
(2008). The Safety of Dose-Dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Trastuzumab in HER-2/neu Overexpressed/Amplified Breast Cancer. JCO
26: 1216-1222
[Abstract][Full Text]
Ganz, P. A., Hussey, M. A., Moinpour, C. M., Unger, J. M., Hutchins, L. F., Dakhil, S. R., Giguere, J. K., Goodwin, J. W., Martino, S., Albain, K. S.
(2008). Late Cardiac Effects of Adjuvant Chemotherapy in Breast Cancer Survivors Treated on Southwest Oncology Group Protocol S8897. JCO
26: 1223-1230
[Abstract][Full Text]
Perez, E. A., Suman, V. J., Davidson, N. E., Sledge, G. W., Kaufman, P. A., Hudis, C. A., Martino, S., Gralow, J. R., Dakhil, S. R., Ingle, J. N., Winer, E. P., Gelmon, K. A., Gersh, B. J., Jaffe, A. S., Rodeheffer, R. J.
(2008). Cardiac Safety Analysis of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With or Without Trastuzumab in the North Central Cancer Treatment Group N9831 Adjuvant Breast Cancer Trial. JCO
26: 1231-1238
[Abstract][Full Text]
Yuan, W., Wang, W., Cui, B., Su, T., Ge, Y., Jiang, L., Zhou, W., Ning, G.
(2008). Overexpression of ERBB-2 was more frequently detected in malignant than benign pheochromocytomas by multiplex ligation-dependent probe amplification and immunohistochemistry. Endocr Relat Cancer
15: 343-350
[Abstract][Full Text]
Wilson, P. M, Booth, A. M, Eastwood, A., Watt, I. S
(2008). Deconstructing media coverage of trastuzumab (Herceptin): an analysis of national newspaper coverage. JRSM
101: 125-132
[Abstract][Full Text]
Bai, T., Luoh, S.-W.
(2008). GRB-7 facilitates HER-2/Neu-mediated signal transduction and tumor formation. Carcinogenesis
29: 473-479
[Abstract][Full Text]
Lidgren, M., Jonsson, B., Rehnberg, C., Willking, N., Bergh, J.
(2008). Cost-effectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancer. Ann Oncol
19: 487-495
[Abstract][Full Text]
Seethala, R. R., Gooding, W. E., Handler, P. N., Collins, B., Zhang, Q., Siegfried, J. M., Grandis, J. R.
(2008). Immunohistochemical Analysis of Phosphotyrosine Signal Transducer and Activator of Transcription 3 and Epidermal Growth Factor Receptor Autocrine Signaling Pathways in Head and Neck Cancers and Metastatic Lymph Nodes. Clin. Cancer Res.
14: 1303-1309
[Abstract][Full Text]
Hyun, C L, Lee, H E, Kim, K S, Kim, S-W, Kim, J H, Choe, G, Park, S Y
(2008). The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer. J. Clin. Pathol.
61: 317-321
[Abstract][Full Text]
Ravel, D., Dubois, V., Quinonero, J., Meyer-Losic, F., Delord, J., Rochaix, P., Nicolazzi, C., Ribes, F., Mazerolles, C., Assouly, E., Vialatte, K., Hor, I., Kearsey, J., Trouet, A.
(2008). Preclinical Toxicity, Toxicokinetics, and Antitumoral Efficacy Studies of DTS-201, a Tumor-Selective Peptidic Prodrug of Doxorubicin. Clin. Cancer Res.
14: 1258-1265
[Abstract][Full Text]
Takeuchi, E. E., Alison, D. L.
(2008). What's new in oncology: targeted therapy. Contin Educ Anaesth Crit Care Pain
8: 36-38
[Full Text]
Tran, L.-P. P., Grabinski, J. L.
(2008). Chemotherapy for Early-Stage Breast Cancer: A Paradigm in Flux. Journal of Pharmacy Practice
21: 46-56
[Abstract]
Vahid, B., Marik, P. E.
(2008). Pulmonary Complications of Novel Antineoplastic Agents for Solid Tumors. Chest
133: 528-538
[Abstract][Full Text]
Azambuja, E., Durbecq, V., Rosa, D. D., Colozza, M., Larsimont, D., Piccart-Gebhart, M., Cardoso, F.
(2008). HER-2 overexpression/amplification and its interaction with taxane-based therapy in breast cancer. Ann Oncol
19: 223-232
[Abstract][Full Text]
Peoples, G. E., Holmes, J. P., Hueman, M. T., Mittendorf, E. A., Amin, A., Khoo, S., Dehqanzada, Z. A., Gurney, J. M., Woll, M. M., Ryan, G. B., Storrer, C. E., Craig, D., Ioannides, C. G., Ponniah, S.
(2008). Combined Clinical Trial Results of a HER2/neu (E75) Vaccine for the Prevention of Recurrence in High-Risk Breast Cancer Patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin. Cancer Res.
14: 797-803
[Abstract][Full Text]
Contessa, J. N., Hamstra, D. A.
(2008). Revoking the Privilege: Targeting HER2 in the Central Nervous System. Mol. Pharmacol.
73: 271-273
[Abstract][Full Text]
Wang, Y., Ikeda, D. M., Narasimhan, B., Longacre, T. A., Bleicher, R. J., Pal, S., Jackman, R. J., Jeffrey, S. S.
(2008). Estrogen Receptor-Negative Invasive Breast Cancer: Imaging Features of Tumors with and without Human Epidermal Growth Factor Receptor Type 2 Overexpression. Radiology
246: 367-375
[Abstract][Full Text]
Wong, D. J., Nuyten, D. S.A., Regev, A., Lin, M., Adler, A. S., Segal, E., van de Vijver, M. J., Chang, H. Y.
(2008). Revealing Targeted Therapy for Human Cancer by Gene Module Maps. Cancer Res.
68: 369-378
[Abstract][Full Text]
Roukos, D. H., Ferretti, G., Felici, A., Cognetti, F., Mehta, R., Nash, I., Hayes, D. F., Berry, D., Moore, A.
(2008). HER2 and Response to Paclitaxel in Node-Positive Breast Cancer. NEJM
358: 197-199
[Full Text]
Paik, S., Taniyama, Y., Geyer, C. E. Jr
(2008). Anthracyclines in the Treatment of HER2-Negative Breast Cancer. JNCI J Natl Cancer Inst
100: 2-4
[Full Text]
Shrim, A., Garcia-Bournissen, F., Maxwell, C., Farine, D., Koren, G.
(2008). Trastuzumab treatment for breast cancer during pregnancy. cfp
54: 31-32
[Abstract][Full Text]
Bradbury, P. A., Heist, R. S., Kulke, M. H., Zhou, W., Marshall, A. L., Miller, D. P., Su, L., Park, S., Temel, J., Fidias, P., Sequist, L., Lynch, T. J., Wain, J. C., Shepherd, F. A., Christiani, D. C., Liu, G.
(2008). A Rapid Outcomes Ascertainment System Improves the Quality of Prognostic and Pharmacogenetic Outcomes from Observational Studies. Cancer Epidemiol. Biomarkers Prev.
17: 204-211
[Abstract][Full Text]
Revillion, F., Lhotellier, V., Hornez, L., Bonneterre, J., Peyrat, J.-P.
(2008). ErbB/HER ligands in human breast cancer, and relationships with their receptors, the bio-pathological features and prognosis. Ann Oncol
19: 73-80
[Abstract][Full Text]
Bird, B. R.J. H., Swain, S. M.
(2008). Cardiac Toxicity in Breast Cancer Survivors: Review of Potential Cardiac Problems. Clin. Cancer Res.
14: 14-24
[Abstract][Full Text]
Wolff, A. C., Paik, S., Press, M. F.
(2008). HER2 as a Predictive Marker: Why Bother Testing?. Am Soc Clin Oncol Ed Book
2008: 25-28
[Abstract][Full Text]
Dawood, S., Broglio, K., Kau, S.-W., Islam, R., Symmans, W. F., Buchholz, T. A., McGuire, S. E., Meric-Bernstam, F., Cristofanilli, M., Hortobagyi, G. N., Gonzalez-Angulo, A. M.
(2008). Prognostic Value of Initial Clinical Disease Stage After Achieving Pathological Complete Response. The Oncologist
13: 6-15
[Abstract][Full Text]
Hofmann, M, Stoss, O, Gaiser, T, Kneitz, H, Heinmoller, P, Gutjahr, T, Kaufmann, M, Henkel, T, Ruschoff, J
(2008). Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy. J. Clin. Pathol.
61: 89-94
[Abstract][Full Text]
Saad, A., Beto, R., Abraham, J., Remick, S. C.
(2008). Cardiovascular Safety and Toxicity Profile of New Molecularly Targeted Anticancer Agents. Am Soc Clin Oncol Ed Book
2008: 428-434
[Abstract][Full Text]
Varchetta, S., Gibelli, N., Oliviero, B., Nardini, E., Gennari, R., Gatti, G., Silva, L. S., Villani, L., Tagliabue, E., Menard, S., Costa, A., Fagnoni, F. F.
(2007). Elements Related to Heterogeneity of Antibody-Dependent Cell Cytotoxicity in Patients Under Trastuzumab Therapy for Primary Operable Breast Cancer Overexpressing Her2. Cancer Res.
67: 11991-11999
[Abstract][Full Text]
Munoz, A., Carrera, S., Ferreiro, J., Ruiz de Lobera, A., Mane, J. M., Lopez-Vivanco, G.
(2007). Reversible liver toxicity with adjuvant trastuzumab for localized breast cancer. Ann Oncol
18: 2045-2046
[Full Text]
Veneziani, B. M., Criniti, V., Cavaliere, C., Corvigno, S., Nardone, A., Picarelli, S., Tortora, G., Ciardiello, F., Limite, G., De Placido, S.
(2007). In vitro expansion of human breast cancer epithelial and mesenchymal stromal cells: optimization of a coculture model for personalized therapy approaches. Molecular Cancer Therapeutics
6: 3091-3100
[Abstract][Full Text]
Sapino, A., Montemurro, F., Marchio, C., Viale, G., Kulka, J., Donadio, M., Bottini, A., Botti, G., dei Tos, A. P., Bersiga, A., Di Palma, S., Truini, M., Sanna, G., Aglietta, M., Bussolati, G.
(2007). Patients with advanced stage breast carcinoma immunoreactive to biotinylated Herceptin(R) are most likely to benefit from trastuzumab-based therapy: an hypothesis-generating study. Ann Oncol
18: 1963-1968
[Abstract][Full Text]
Catania, C., Medici, M., Magni, E., Munzone, E., Cardinale, D., Adamoli, L., Sanna, G., Minchella, I., Radice, D., Goldhirsch, A., Nole, F.
(2007). Optimizing clinical care of patients with metastatic breast cancer: a new oral vinorelbine plus trastuzumab combination. Ann Oncol
18: 1969-1975
[Abstract][Full Text]
Widakowich, C., de Castro, G. Jr., de Azambuja, E., Dinh, P., Awada, A.
(2007). Review: Side Effects of Approved Molecular Targeted Therapies in Solid Cancers. The Oncologist
12: 1443-1455
[Abstract][Full Text]
Ignatiadis, M., Xenidis, N., Perraki, M., Apostolaki, S., Politaki, E., Kafousi, M., Stathopoulos, E. N., Stathopoulou, A., Lianidou, E., Chlouverakis, G., Sotiriou, C., Georgoulias, V., Mavroudis, D.
(2007). Different Prognostic Value of Cytokeratin-19 mRNA Positive Circulating Tumor Cells According to Estrogen Receptor and HER2 Status in Early-Stage Breast Cancer. JCO
25: 5194-5202
[Abstract][Full Text]
Harris, L., Fritsche, H., Mennel, R., Norton, L., Ravdin, P., Taube, S., Somerfield, M. R., Hayes, D. F., Bast, R. C. Jr
(2007). American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer. JCO
25: 5287-5312
[Abstract][Full Text]
Grothey, A.
(2007). Biological Therapy and Other Novel Therapies in Early-Stage Disease: Are They Appropriate?. Clin. Cancer Res.
13: 6909s-6912s
[Abstract][Full Text]
Arnould, L., Arveux, P., Couturier, J., Gelly-Marty, M., Loustalot, C., Ettore, F., Sagan, C., Antoine, M., Penault-Llorca, F., Vasseur, B., Fumoleau, P., Coudert, B. P.
(2007). Pathologic Complete Response to Trastuzumab-Based Neoadjuvant Therapy Is Related to the Level of HER-2 Amplification. Clin. Cancer Res.
13: 6404-6409
[Abstract][Full Text]
Winer, E. P., Harris, J. R., Smith, B. L., D'Alessandro, H. A., Brachtel, E. F.
(2007). Case 32-2007 -- A 62-Year-Old Woman with a Second Breast Cancer. NEJM
357: 1640-1648
[Full Text]
Hayes, D. F., Thor, A. D., Dressler, L. G., Weaver, D., Edgerton, S., Cowan, D., Broadwater, G., Goldstein, L. J., Martino, S., Ingle, J. N., Henderson, I. C., Norton, L., Winer, E. P., Hudis, C. A., Ellis, M. J., Berry, D. A., the Cancer and Leukemia Group B (CALGB) Investiga,
(2007). HER2 and Response to Paclitaxel in Node-Positive Breast Cancer. NEJM
357: 1496-1506
[Abstract][Full Text]
Moore, A.
(2007). Breast-Cancer Therapy -- Looking Back to the Future. NEJM
357: 1547-1549
[Full Text]
Jones, L. W., Haykowsky, M. J., Swartz, J. J., Douglas, P. S., Mackey, J. R.
(2007). Early Breast Cancer Therapy and Cardiovascular Injury. J Am Coll Cardiol
50: 1435-1441
[Abstract][Full Text]
Ihemelandu, C. U., Leffall, L. D. Jr., Dewitty, R. L., Naab, T. J., Mezghebe, H. M., Makambi, K. H., Adams-Campbell, L., Frederick, W. A.
(2007). Molecular Breast Cancer Subtypes in Premenopausal African-American Women, Tumor Biologic Factors and Clinical Outcome. Ann. Surg. Oncol.
14: 2994-3003
[Abstract][Full Text]
Emlet, D. R., Brown, K. A., Kociban, D. L., Pollice, A. A., Smith, C. A., Ong, B. B. L., Shackney, S. E.
(2007). Response to trastuzumab, erlotinib, and bevacizumab, alone and in combination, is correlated with the level of human epidermal growth factor receptor-2 expression in human breast cancer cell lines. Molecular Cancer Therapeutics
6: 2664-2674
[Abstract][Full Text]
Lu, C.-H., Wyszomierski, S. L., Tseng, L.-M., Sun, M.-H., Lan, K.-H., Neal, C. L., Mills, G. B., Hortobagyi, G. N., Esteva, F. J., Yu, D.
(2007). Preclinical Testing of Clinically Applicable Strategies for Overcoming Trastuzumab Resistance Caused by PTEN Deficiency. Clin. Cancer Res.
13: 5883-5888
[Abstract][Full Text]
Jones, L. W., Haykowsky, M., Pituskin, E. N., Jendzjowsky, N. G., Tomczak, C. R., Haennel, R. G., Mackey, J. R.
(2007). Cardiovascular Reserve and Risk Profile of Postmenopausal Women After Chemoendocrine Therapy for Hormone Receptor Positive Operable Breast Cancer. The Oncologist
12: 1156-1164
[Abstract][Full Text]
Blackburn, G. L, Wang, K. A
(2007). Dietary fat reduction and breast cancer outcome: results from the Women's Intervention Nutrition Study (WINS). Am. J. Clin. Nutr.
86: 878S-881S
[Abstract][Full Text]
Previous
